Picard Medical Marks Public Company Milestone by Ringing the NYSE Opening Bell - Picard Medical, Inc. / SynCardia Systems LLC commemorate the Company's transition to the public markets and continued advancement of their

Medical Marks Public Company Milestone by Ringing the NYSE Opening Bell

Picard Medical, Inc. / SynCardia Systems LLC commemorate the Company's transition

to the public markets and continued advancement

of their Total Artificial Heart technology -

Ariz., Dec. 18, 2025 - Picard Medical, Inc. (NYSE: PMI) ("Picard" or the "Company"), parent

company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. Food and Drug

Administration (FDA) and Health Canada, today announced that it will ring the Opening Bell at the New York Stock Exchange on

December 18, 2025, marking the Company's transition to the public markets and its continued commitment to advancing total

artificial heart therapy for patients with end-stage heart failure.

are proud to mark Picard Medical's transition to a newly public company," said Patrick NJ Schnegelsberg Chief Executive Officer

of Picard Medical. "Our technology has supported patients worldwide and becoming a public company strengthens our ability to advance

our artificial heart platform including the fully implantable Emperor system. This marks an important next phase as we build on decades

of clinical leadership pioneering the world's first life-sustaining total artificial heart, advancing our next-generation technology

and creating long-term value."

Picard Medical and SynCardia

Medical, Inc. is the parent company of SynCardia Systems, LLC ("SynCardia"), the Tucson, Arizona-based leader with

the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures,

and commercializes the SynCardia Total Artificial Heart ("STAH"), an implantable system that assumes the full functions of

a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only

commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across

27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world.

additional information about Picard Medical, please visit www.picardmedical.com or review the Company's filings

with the U.S. Securities and Exchange Commission at www.sec.gov.

press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that

are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to

differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates

or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with respect

thereto or any change in events, conditions, or circumstances on which any statement is based. Forward-looking statements are subject

to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of

the Registration Statement and related prospectus filed in connection with the initial public offering with the SEC. Copies are available

on the SEC's website, http://www.sec.gov.

LifeSci Advisors LLC

Medical, Inc./SynCardia Systems, LLC